Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Cristina SauraJudit MatitoMafalda OliveiraHans P M W WildiersAdam M BrufksySimon H WatersSara A HurvitzBeverly MoySung-Bae KimWilliam J GradisharGeraldo Silva QueirozEduardo Henrique CronembergerGerald J WallweberJudith BebchukKiana KeyvanjahAlshad S LalaniRichard BryceAna VivancosLisa D EliSuzette DelalogePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
PIK3CA mutations were associated with shorter PFS whereas higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C compared with L+C.